Pediatric Neurology Department, Health Sciences University Dr. Behçet Uz Children's Education and Research Hospital, Alsancak, 35210, Izmir, Turkey.
Pediatric Endocrinology Department, Health Sciences University Dr. Behçet Uz Children's Education and Research Hospital, Izmir, Turkey.
Neurol Sci. 2021 Dec;42(12):5261-5269. doi: 10.1007/s10072-021-05225-y. Epub 2021 Apr 12.
Ketogenic diet (KD) remains a valuable treatment option for children with drug-resistant epilepsy. However, it may cause many well-known adverse effects such as dyslipidemia or kidney stones. But, its effects on thyroid functions are largely unknown.
The aim of this study was to investigate the effects of the KD on thyroid functions in children with drug-resistant epilepsy.
A total of 66 children (35 females) aged 3-193 months (median, 52 months) with drug-resistant epilepsy who received a KD for at least 12 months were enrolled in the study. All children were started on KD with 3:1 ratio which was then adjusted as clinically necessary. Serum free-thyroxine (FT4) and thyroid stimulating hormone (TSH) concentrations were measured before starting treatment and at the first, sixth and twelfth months of treatment. Changes in FT4 and TSH concentrations over 12 months were analyzed.
Median serum FT4 and TSH concentrations, and the frequencies of patients with low FT4 and high TSH concentrations did not change significantly in the study sample over the 12-month study period. Serum FT4 levels increased significantly and TSH concentrations decreased insignificantly in four patients receiving L-thyroxine replacement therapy. During the 12-month treatment period, BMI-SDS increased, and the number of antiepileptic drugs decreased significantly.
It appears that KD therapy does not impair thyroid functions in children with drug-resistant epilepsy. KD can be used safely along with L-thyroxine replacement even in children with pre-existing subclinical hypothyroidism.
生酮饮食(KD)仍然是治疗耐药性癫痫儿童的有价值的治疗选择。然而,它可能会引起许多众所周知的不良反应,如血脂异常或肾结石。但是,其对甲状腺功能的影响在很大程度上尚不清楚。
本研究旨在探讨 KD 对耐药性癫痫儿童甲状腺功能的影响。
共纳入 66 名(35 名女性)年龄为 3-193 个月(中位数为 52 个月)的耐药性癫痫儿童,他们接受 KD 治疗至少 12 个月。所有儿童均开始接受 3:1 比例的 KD,然后根据临床需要进行调整。在开始治疗前以及治疗的第 1、6 和 12 个月测量血清游离甲状腺素(FT4)和促甲状腺激素(TSH)浓度。分析 12 个月内 FT4 和 TSH 浓度的变化。
在研究期间,研究样本中 FT4 和 TSH 浓度的中位数以及低 FT4 和高 TSH 浓度患者的频率在 12 个月内没有显著变化。在接受左甲状腺素替代治疗的四名患者中,血清 FT4 水平显著升高,TSH 浓度略有下降。在 12 个月的治疗期间,BMI-SDS 增加,抗癫痫药物的数量显著减少。
KD 治疗似乎不会损害耐药性癫痫儿童的甲状腺功能。KD 可以与左甲状腺素替代治疗安全地联合使用,即使在存在亚临床甲状腺功能减退症的儿童中也是如此。